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Abstract
Despite showing promise in preclinical models, anti–Staphylococcus aureus vaccines have failed 
in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, 
vaccines exclusively inducing cellular immunity have not been studied to formally test whether a 
cellular-only response can protect against infection. We demonstrate that nasal vaccination with 
targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic 
S. aureus infection in the absence of any antigen-specific antibodies. These findings can help 
inform future developments in staphylococcal vaccine development and studies into the 
requirements for protective immunity against S. aureus.
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Infections caused by antibiotic-resistant Staphylococcus aureus are causing a global 
epidemic and present an urgent and unmet need for effective vaccines [1]. Although a 
number of vaccines were effective in preclinical challenge models, these subsequently failed 
in clinical trials [2] due at least in part to a lack of insight into what constitutes protective 
immunity in the human host. Until recently, anti–S. aureus vaccine approaches have focused 
on the induction of neutralizing/opsonizing antibodies, but there is increasing evidence that 
cellular immunity may be equally or more important for protective immunity [3]. Indeed, 
vaccines expanding T-helper type 1 (Th1) and T-helper type 17 (Th17) cells conferred 
protection in murine models of S. aureus infection [4]. However, to date, systems that 
exclusively induce cellular immunity in the absence of humoral immunity have not been 
studied to determine if a cellular-only response can protect against systemic staphylococcal 
infection.
Because mucosal vaccination can potentially stimulate an immune response both at the 
mucosae and systemically, and has the advantage of being needle-free, our objective was to 
design a mucosal S. aureus vaccine that selectively promoted cellular immunity. Initiating an 
immune response at the mucosae is hindered by several factors, particularly poor uptake 
across epithelial barriers. Targeting mucosal antigen-sampling microfold (M) cells is a 
promising approach to address inefficient transepithelial vaccine uptake [5]. Ulex europaeus 
agglutinin I (UEA-1), a fucose binding lectin from gorse, binds to [6] and can enhance the 
transcytosis of nanoparticles across M cells [7], potentially delivering the attached antigen to 
subepithelial dendritic cells. Thus, we investigated the potential of targeting particulate 
vaccines to M cells with UEA-1 and a UEA-1 peptidomimetic (UEA-1m) [8].
METHODS
Animals
Female BALB/c and C57BL/6 mice were obtained from Harlan Laboratories and Charles 
River Laboratories and were used at 8–16 weeks of age. Animals were maintained in a 
specific pathogen-free environment at the TCD Bioresource facility. All mice were 
maintained according to European Union regulations, and experiments were performed 
under license from the Irish Department of Health and Children and with approval from the 
Trinity College Dublin Bioresources Ethics Committee.
Materials
Streptavidin-coated polystyrene nanoparticles (300–390 nm) were supplied by Spherotech 
Inc and Corpuscular Inc. Biotinylated UEA-1m (synthesized by Polypeptide), and 
ovalbumin (OVA) antigen (Sigma) were both provided as lyophilized powders and 
reconstituted in endotoxin-free phosphate-buffered saline (PBS). The A domain of clumping 
factor A (ClfA; amino acids 40–559) was expressed as a hexahistidine-tagged recombinant 
protein and purified by Ni2+ chelate chromatography. Both OVA and ClfA antigens were 
biotinylated with the EZ-Link Sulfo-NHS-LC biotinylation kit (Thermo Scientific). 
Cytokine and antibody enzyme-linked immunosorbent assay (ELISA) detection kits were 
obtained from R&D Systems, BD Pharmingen, and BioLegend. Complete RPMI (cRPMI) 
comprised RPMI 1640 (BioSera), 10% fetal calf serum (BioSera), 1% penicillin-
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streptomycin (Invitrogen), and 1% L-glutamine (Invitrogen). Fluorescently conjugated 
antibodies for flow cytometry were purchased from BD Biosciences (anti–interleukin 17A 
[IL-17A] PerCP-Cy 5 clone TC11-18H10) and eBiosciences (anti–interferon [IFN]–γ PE 
Cy7 clone XMG 1.2). Quil A saponin was obtained from Brenntag, and the fractionated 
derivative of Quil A (QS21) was provided by the Vaccine Formulation Laboratory in 
Lausanne, Switzerland.
Vaccine Formulations
Biotinylated antigen (OVA or ClfA) and biotinylated UEA-1m were incubated with 
streptavidin-coated polystyrene nanoparticles for 1 hour at room temperature in sodium 
phosphate buffer (pH 5.5). Fifty micrograms of OVA was administered by oral vaccination, 
but 10 μg OVA and 2 μg ClfA was sufficient for intranasal vaccine formulations (adequate 
quantity to induce a cellular response to targeted nanoparticles). UEA-1m was incorporated 
at 10 μg per vaccine formulation (attached to nanoparticles). Protein attachment was 
determined by bicinchoninic assay (Thermo Scientific) of the supernatant, and the particles 
were resuspended in PBS (pH 7.4) before use. The contents of each formulation are detailed 
in the Figure legends.
Immunization Strategies
Groups of mice (n = 5) were immunized orally on 3 consecutive days (days 0, 1, and 2) and 
boosted 3 weeks later (days 21, 22, and 23) with PBS only, OVA (50 μg) nanoparticles, or 
OVA (50 μg) + UEA-1m (50 μg) nanoparticles. Mice were immunized intranasally on days 
0, 14, and 28 by dropping the vaccine formulation (20 μL maximum volume containing 
OVA or ClfA antigen in solution or particulate form) onto each nostril and allowing the 
animal to inhale the vaccine. Group sizes for mucosal vaccinations and challenge were 
determined based on our previous experience and published reports [9, 10]. Blood samples 
were taken from the tail vein before each immunization for analysis of antibody production. 
Tissues were isolated after killing, the cells isolated by mechanical disruption, and 
restimulated with antigen in vitro.
Measuring the Cellular and Humoral Response to Antigen
Antigen-specific antibody titers in the serum and nasal washes, and cytokine secretion by 
restimulated lymphocytes (cultured for 72 hours) were determined by sandwich ELISA as 
described previously [9]. All samples were analyzed in triplicate. Cytokine production by 
CD3+CD4+ and CD3+CD8+ T cells was detected by restimulating the cells for 6 hours in 
vitro in cRPMI with or without antigen. Brefeldin A (10 μg/mL; Sigma) was added to the 
culture after 1 hour to prevent cytokine export from the cells. After 6 hours the T cells were 
labeled with anti-CD3, anti-CD4, and anti-CD8 fluorophore-conjugated antibodies. 
Following fixation and permeabilization with FIX&PERM (ADG Bioresearch GmbH), 
intracellular IFN-γ and IL-17 were labeled. Data were acquired with a FACSCanto II (BD 
Biosciences) and analyzed using FlowJo software (TreeStar Inc).
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Measuring Neutralizing Antibodies in Serum
The presence of neutralizing antibodies was determined by testing the ability of serum from 
immunized mice to inhibit the adherence of S. aureus to fibrinogen. Microtiter plates were 
coated with fibrinogen (2 μg/mL) overnight at 4°C and blocked for 2 hours at 37°C with 5% 
(w/v) bovine serum albumin. Staphylococcus aureus PS80 was grown to stationary phase, 
washed, and incubated with mouse serum (1:60 dilution) for 30 minutes at room temperature 
before being added to the wells of a fibrinogen-coated plate and incubated for 1.5 hours at 
37°C. After washing with PBS, adherent cells were fixed with formaldehyde (25% v/v) and 
stained with crystal violet, and the A570 nm was measured. Adherence was expressed as a 
percentage of bacterial adherence in the absence of serum, and percentage of inhibition was 
determined by subtracting the percentage adherence values from 100.
Staphylococcus aureus Infection
Staphylococcus aureus PS80 has been previously described [10]. Staphylococci were 
cultivated from frozen stocks on Columbia agar with 2% NaCl. Bacteria were resuspended 
to an appropriate concentration in PBS. Nasally immunized C57BL/6 mice were infected 
with a sublethal inoculum of S. aureus (5 × 108 colony-forming units [CFU]) by 
intraperitoneal injection, on day 36, and were sacrificed 3, 24, and 72 hours postinfection (5 
mice per treatment group, per timepoint; group size was determined through optimization of 
the challenge model [10]). At specific timepoints postchallenge, the peritoneal cavity was 
lavaged with sterile PBS and the kidneys and spleens were harvested and homogenized in 
PBS. Serial dilutions of the peritoneal exudates and organ homogenates were prepared and 
plated onto tryptic soy agar to determine the numbers of S. aureus CFU. Serum was 
collected from each mouse 1 day prior to each vaccination for analysis of antibody titers. To 
quantify phagocyte infiltration, total leukocytes isolated from the peritoneal exudates were 
enumerated using a hemocytometer and were then stained with monoclonal antibodies 
against neutrophil (CD11b+Ly6G+F4/80−) and macrophage (CD11b+Ly6G−F4/80+) surface 
markers before analysis by flow cytometry (BD FACSCalibur).
Statistical Analysis
Data are presented as mean (±SEM) from 5 mice per experimental group, tested individually 
in triplicate. P < .05, P < .01, and P < .001 denote statistical significance between groups by 
1-way analysis of variance and Tukey posttest, or by 1-tailed unpaired Student t test, as 
specified in the Figure legends.
RESULTS AND DISCUSSION
Nasal vaccination with UEA-1m-targeted, antigen (OVA)–loaded nanoparticles (300-390 nm 
diameter) promoted enhanced antigen-specific T-cell responses compared to antigen 
conjugated to nontargeted particles (Figure 1A). The most striking finding was the Th1- and 
Th17-biased response elicited by targeted nanoparticles (Figure 1A), without the induction 
of any detectable antigen-specific serum immunoglobulin G (IgG) (Figure 1B). Similarly, 
oral vaccination with UEA-1m-targeted nanoparticles enhanced antigen-specific cellular 
responses (Supplementary Figure 1), compared to untargeted nanoparticles in the absence of 
a detectable antibody response. In contrast, antibodies were readily induced both 
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systemically (serum IgG) and locally (nasal wash immunoglobulin A [IgA]) following 
intranasal administration of OVA in combination with Quil A, a potent saponin adjuvant 
[11], or QS21 (Figure 1C), an adjuvant active fraction of Quil A that displays reduced 
toxicity [11]. Our findings support a report that UEA-1 targeting of a nasal human 
immunodeficiency virus vaccine elicited enhanced cellular responses [12] but differs in that 
our system did not induce any local or systemic humoral immunity.
Having identified a mucosal adjuvant formulation that selectively promoted T-cell responses, 
we generated a model anti–S. aureus vaccine, based on UEA-1m–targeted nanoparticles 
coupled with the S. aureus surface antigen ClfA, and investigated its efficacy in protection 
against systemic S. aureus infection. ClfA is an important S. aureus virulence factor, which 
promotes bacterial adherence to fibrinogen [13]. Whereas immunization of mice with 
recombinant ClfA A domain formulated with Freund’s complete adjuvant induced protective 
humoral immunity [13], protection was IL-17A–dependent following injection of the 
antigen in alum adjuvant [14]. These reports highlight the promise of this ubiquitously 
expressed staphylococcal surface protein as a candidate antigen for the induction of 
protective cell-mediated immunity. In line with this, a vaccine based on a Candida albicans 
surface protein with structural similarity to ClfA [15] induced protective anti–S. aureus 
immunity that was critically dependent on the induction of Th1 and Th17 responses [4].
Initially, we investigated whether UEA-1m-targeted ClfA-loaded nanoparticles could 
promote antigen-specific T-cell responses in the absence of antibodies. As in the case of 
OVA, UEA-1m targeting significantly enhanced ClfA-specific IFN-γ and IL-17 production 
(Figure 1D). Splenic CD3+CD4+ and CD3+CD8+ T cells from targeted nanoparticle-
vaccinated mice produced IFN-γ and IL-17 upon in vitro restimulation with ClfA, as 
reflected in an increased percentage of antigen-specific cytokine-producing T cells and a 
greater fold increase in cytokine-producing T cells vs controls (Figure 1E, F). Anti-ClfA 
antibodies were undetectable in serum samples from animals vaccinated with ClfA-loaded, 
UEA-1m–targeted nanoparticles, whereas high titers of antigen-specific serum IgG, IgA 
(Figure 1G), and function-neutralizing antibodies capable of blocking the adherence of 
ClfA-expressing bacteria to fibrinogen were elicited by vaccination with ClfA and QS21 
(Figure 1H).
Having established the ability of the ClfA-loaded, UEA-1m-targeted nanoparticles to elicit 
ClfA-specific cellular immune responses in the complete absence of any specific humoral 
immunity, we next determined the ability of this vaccine to induce protective immunity 
against systemic S. aureus infection. Groups of mice were nasally immunized with either 
ClfA on UEA-1m–targeted nanoparticles or ClfA with QS21 prior to intraperitoneal 
challenge with a sublethal dose of S. aureus (Figure 2A). Bacterial load both locally at the 
site of infection (peritoneal cavity) and systemically (kidneys and spleen) was reduced in 
both vaccinated groups over the course of infection (Figure 2B, Supplementary Figure 2), 
with a significant (approximately 2 log) reduction in systemic bacterial dissemination to the 
kidneys at 72 hours postinfection, in animals receiving either vaccine compared to 
unvaccinated control animals (Figure 2C, Supplementary Figure 2).
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Antigen-specific serum antibody titers induced by the QS21-adjuvanted vaccine remained 
stable over the course of immunization, and neutralizing antibodies were still present 72 
hours postinfection but were completely undetectable in animals receiving the UEA-1m–
targeted nanoparticle vaccine (Figure 2D and E). In addition to promoting T-cell responses 
(Figure 1D), immunization with ClfA on UEA-1m-targeted nanoparticles also increased 
local infiltration of neutrophils and macrophages to the peritoneal cavity (Figure 2F) at 72 
hours postinfection compared to unvaccinated animals. In contrast, there was no significant 
increase in phagocyte infiltration to the peritoneal cavity in animals that received the QS21-
adjuvanted vaccine (Supplementary Figure 2C).
Remarkably, these data demonstrate that a targeted nasal vaccine promotes clearance of an 
acute S. aureus systemic infection, but also that a purely cellular response is sufficient for 
this protection. This is the first formal demonstration that vaccine-induced S. aureus antigen-
specific cellular immunity in the absence of detectable antibody responses can protect 
against staphylococcal infection and expands upon previously published work indicating the 
importance of cellular immunity in vaccine-induced protection against S. aureus infection 
[4, 15]. Our targeted mucosal vaccine approach will prove a valuable tool not only in 
dissecting protective immunity to S. aureus but also for other bacterial infections where Th1 
and Th17 responses have been shown to contribute to protective immunity, including 
Bordetella pertussis and Streptococcus pneumoniae.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Lectin-targeted mucosal delivery of nanoparticulate antigens induces strong T-cell responses 
in the absence of a humoral response. Mice were immunized intranasally on days 1, 14, and 
28 with phosphate-buffered saline (PBS) only as a control or ovalbumin (OVA; 10 μg) with 
or without Ulex europaeus agglutinin I peptidomimetic (UEA-1m; 10 μg), attached to 
nanoparticles (NP). A, Antigen-specific responses by cells isolated from the cervical lymph 
nodes were determined on day 35, by ex vivo restimulation with OVA (500 μg/mL) for 72 
hours, and subsequent enzyme-linked immunosorbent assay (ELISA) to determine cytokine 
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production. Mean ± SEM. *P < .05 vs nontargeted particles; 1-way analysis of variance 
(ANOVA) and Tukey posttest (n = 5). B, Serum samples harvested from blood taken on day 
35 were analyzed for the presence of OVA-specific immunoglobulin G (IgG). Each data 
point represents an individual animal. C, Nasal delivery of QS21-adjuvanted OVA promotes 
humoral immunity. Mice were immunized intranasally on days 1, 14, and 28 with PBS or 
OVA (10 μg) either in solution or conjugated to nanoparticles with UEA-1m (10 μg), or with 
OVA and Quil A saponin or a purified derivative of Quil A (QS21), both at 10 μg per dose. 
Blood and nasal cavity washes were taken on day 35. Antigen (OVA)–specific antibody 
titers were determined by ELISA. Each data point represents an individual animal (n = 5); 
the black bars denote the mean. *P < .05, **P < .01, and ***P < .001 vs antigen alone; 1-
way ANOVA and Tukey posttest (n = 5). D–H, Nasal immunization with Staphylococcus 
aureus clumping factor A (ClfA). Female C57BL/6 mice were immunized intranasally on 
days 1, 14, and 28 with ClfA (2 μg) attached to nanoparticles alone or targeted with 
UEA-1m (10 μg). Antigen-specific responses by cells isolated from the spleen were 
determined on day 35, by ex vivo restimulation with ClfA (10 μg/mL), and subsequent 
ELISA (D) and intracellular staining (E and F) to determine cytokine production. Antigen-
specific responses by splenic CD3+CD8+ and CD3+CD4+ T cells were assessed by ex vivo 
restimulation of the cells with ClfA for 6 hours, and subsequent flow cytometric analysis of 
interferon (IFN)-γ and interleukin 17 (IL-17)–producing cells. Representative dotplots 
showing the percentage of IFN-γ or IL-17–producing T cells. Unstimulated cells are on the 
left of each panel, ClfA-stimulated cells on the right. Pooled data showing the fold change in 
percentage of cytokine-producing T cells in the spleen (compared to unstimulated control). 
G, Anti-ClfA IgG antibody titers were assessed by ELISA in day 35 serum and nasal wash 
samples. The presence of neutralizing antibodies was determined by measuring the ability of 
serum to inhibit ClfA-mediated S. aureus adherence to fibrinogen. Staphylococcus aureus 
was preincubated with serum, and adherence to fibrinogen was calculated as a percentage of 
values measured in control wells lacking serum. Data are representative of 2–3 independent 
experiments. Each data point represents an individual animal; the black bars denote the 
mean. ***P < .001 by 1-way ANOVA and Tukey posttest (n = 5).
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Figure 2. 
The induction of cellular immunity by a nasal targeted nanoparticulate Staphylococcus 
aureus vaccine is sufficient for clearance of a systemic S. aureus infection. A, Immunization 
strategy. Mice were immunized intranasally on days 1, 14, and 28 with phosphate-buffered 
saline (PBS) or with clumping factor A (ClfA; 2 μg) and Ulex europaeus agglutinin I 
peptidomimetic (UEA-1m; 10 μg) attached to nanoparticles (NP). Mice were sacrificed at 
time 0 (day 35, before infection), and at 3, 24, and 72 hours after intraperitoneal infection 
with 5 × 108 colony-forming units (CFU) S. aureus (strain PS80). Data are representative of 
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2 independent experiments. B and C, Bacterial counts. The peritoneal exudate, kidneys, and 
spleen were harvested at each time point, homogenized, and cultured, and CFUs were 
determined. CFU burden is expressed as the mean ± SEM over time (n = 5, top panel), and 
in each tissue at 72 hours postinfection. C, Statistical significance between groups is denoted 
by *P < .05 and **P < .01 (1-tailed unpaired Student t test). D and E, Antibody responses 
following challenge. Anti-ClfA immunoglobulin G (IgG) antibody titers were determined by 
enzyme-linked immunosorbent assay on serum samples recovered at each timepoint 
postinfection. The presence of neutralizing antibodies was determined by measuring the 
ability of serum to inhibit ClfA-mediated S. aureus adherence to fibrinogen. Staphylococcus 
aureus was preincubated with serum, and adherence to fibrinogen was calculated as a 
percentage of values measured in control wells lacking serum. Each data point represents an 
individual animal (n = 5); the black bars denote the mean. ***P < .001 by 1-way analysis of 
variance and Tukey posttest. F, Phagocytes at the site of infection. The total numbers of 
peritoneal macrophages and neutrophils in control and vaccinated mice were determined by 
flow cytometry at 3, 24, and 72 hours following infection. *P < .05 by 1-tailed unpaired 
Student t test (n = 5).
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